RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.

What Was Tested

The trial (phase 4) is built around Liraglutide.

To evaluate the differences in weight loss between liraglutide monotherapy and combined with orlistat in overweight/obese patients.

It had two arms (groups): experimental group (experimental) and control group (active comparator).

The registry classes the interventions as drug.

Who Took Part

Enrollment: 120 planned participants were the target.

It was open to people of any sex aged from 18 years up to 65 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: BMI: ≤ 35 kg/m² and ≥ 30 kg/m², or ≥ 27 kg/m² and having at least one obesity-related complication (such as hypertension, type 2 diabetes, dyslipidemia). Voluntarily sign the informed consent form, agreeing to cooperate in completing the 24-week treatment and follow-up. No severe cognitive impairment or mental illness, and able to understand and comply with the research requirements.

The full record lists 3 inclusion and 6 exclusion criteria; among the exclusions: allergy to liraglutide, orlistat or excipients; thyroid diseases: personal or family history of medullary thyroid cancer, or uncontrolled hyperthyroidism/hypothyroidism; gastrointestinal diseases: having gastrointestinal surgery within 3 months, or inflammatory bowel disease or active gastric and duodenal ulcers.

How the Study Was Run

The set-up was randomized, parallel-group and open-label.

Because people in this Liraglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Nothing was hidden in this open-label Liraglutide study: the participants and staff both knew the treatment.

It started in 2026-05-01 with completion listed for 2027-08-31.

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: weight loss (time frame: 6 months).

What This Means in Plain Language

Put simply, this is a phase 4, randomized trial of Liraglutide in 120 people.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Liraglutide compound page, all human trials.